Avaii Wealth Management LLC Sells 1,249 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Avaii Wealth Management LLC cut its position in TG Therapeutics, Inc. (NASDAQ:TGTXFree Report) by 4.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 28,984 shares of the biopharmaceutical company’s stock after selling 1,249 shares during the quarter. Avaii Wealth Management LLC’s holdings in TG Therapeutics were worth $678,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in TGTX. Wellington Management Group LLP raised its holdings in TG Therapeutics by 1.4% in the fourth quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company’s stock worth $53,627,000 after purchasing an additional 43,290 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of TG Therapeutics by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 13,670,944 shares of the biopharmaceutical company’s stock worth $233,500,000 after acquiring an additional 199,770 shares during the last quarter. Los Angeles Capital Management LLC grew its stake in shares of TG Therapeutics by 55.8% during the first quarter. Los Angeles Capital Management LLC now owns 76,616 shares of the biopharmaceutical company’s stock worth $1,165,000 after acquiring an additional 27,437 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in shares of TG Therapeutics by 16.9% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 184,815 shares of the biopharmaceutical company’s stock worth $2,811,000 after acquiring an additional 26,761 shares during the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of TG Therapeutics by 3.9% during the first quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company’s stock worth $538,000 after acquiring an additional 1,322 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Stock Performance

NASDAQ:TGTX traded up $0.01 during trading hours on Thursday, reaching $24.51. The company had a trading volume of 340,524 shares, compared to its average volume of 3,662,615. TG Therapeutics, Inc. has a 1-year low of $6.52 and a 1-year high of $26.41. The firm has a market cap of $3.79 billion, a PE ratio of 106.52 and a beta of 2.21. The business’s 50 day moving average price is $23.04 and its 200-day moving average price is $19.23. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83.

TG Therapeutics (NASDAQ:TGTXGet Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The company had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. During the same period in the previous year, the company posted ($0.34) earnings per share. TG Therapeutics’s revenue for the quarter was up 357.0% on a year-over-year basis. Research analysts forecast that TG Therapeutics, Inc. will post 0.13 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on TGTX. B. Riley boosted their price target on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $49.00 target price on shares of TG Therapeutics in a research report on Wednesday, September 18th. Finally, The Goldman Sachs Group upped their target price on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $31.83.

Get Our Latest Analysis on TG Therapeutics

TG Therapeutics Company Profile

(Free Report)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Read More

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTXFree Report).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.